Juan-Pablo is a partner at Action Potential Venture Capital in Palo Alto, CA, and invests in companies that are pioneering bioelectronic medicines. Juan-Pablo is a Board member of Saluda Medical, SetPoint Medical, Neuspera Medical, Cala Health, and CVRx. He was previously an investor at Morgenthaler Ventures and Lightstone Ventures, where he focused on therapeutic medical devices, digital health, and biopharmaceutical investments. There he served as a Board observer at Ardian (acquired by Medtronic), Twelve (acquired by Medtronic), Holaira, Cabochon Aesthetics (acquired by Ulthera/Merz), and Miramar Labs.
Prior to investing, Juan-Pablo led efforts in R&D and Strategy in Medtronic’s CardioVascular Division, including Pipeline Strategy, White-Space expansion, Business Development, and M&A integration efforts. He was named “Medtronic Inventor of The Year” in 2008, and has 30+ patents, granted or pending. Subsequently, he served on the Global Brand Strategy team at Eli Lilly within the Cardiovascular business.
Juan-Pablo earned an MBA from Stanford Graduate School of Business. He also conducted research in Neuroscience, and in the Neurology Department at Stanford Hospital, while completing an M.S. in Electrical Engineering at Stanford University. He received his B.S. in Electrical Engineering from the University of Massachusetts, Amherst.
Juan-Pablo currently serves on the Board of Directors of the Boston-based non-profit, InnerCity Weightlifting, where the gym is used to replace segregation and isolation with economic mobility and social inclusion, disrupting the system that leads to urban street violence.